ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

isatuximab

Also written as “Isatuximab SAR650984”, “Isatuximab” and “isatuximab SAR650984”.

Its studies are mostly in Multiple Myeloma · Lymphoma · Immune System Diseases · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Anemia, Hemolytic, Autoimmune, led by 3 companies.

Drug pageIsatuximab: every studyAll 73 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 4, 201623 company-led studies, 6 open or runningNext primary completion: Apr 5, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi215 open or runningphase 3since Dec 4, 2016Mar 9, 2010Apr 5, 2027phase 3 · NCT03319667
GlaxoSmithKlineits history only11 open or runningphase 2since Oct 13, 2025Oct 13, 2025none ahead
Hoffmann-La Rocheits history only10 open or runningphase 2since May 31, 2018May 31, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Mar 9, 2010.

  1. Sep 18, 2017Phase 3 study in Multiple MyelomaNCT03319667 · 475 enrolled · United States, Australia, Belgium and more
  2. Dec 5, 2017Phase 2 study in Prostatic NeoplasmsNCT03367819 · 44 enrolled · United States, France, Italy and more
  3. Aug 5, 2018Phase 2 study in NeoplasmsNCT03637764 · 107 enrolled · United States, Belgium, Canada and more
  4. Oct 31, 2018Phase 1 study in Multiple MyelomaNCT03733717 · 25 enrolled · China
  5. Nov 29, 2018Phase 2 study in LymphomaNCT03769181 · 58 enrolled · France, Italy, Netherlands and more
  6. Feb 21, 2019Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT03860844 · 67 enrolled · United States, Argentina, Brazil and more
  7. Aug 2, 2019Phase 1 study in Multiple MyelomaNCT04045795 · 56 enrolled · United States, Australia, Belgium and more
  8. Feb 13, 2020Phase 3 study in Multiple MyelomaNCT04270409 · 337 enrolled · United States, Australia, Brazil and more
  9. Feb 19, 2020Phase 2 study in Immune System DiseasesNCT04294459 · 23 enrolled · United States, Spain
  10. Dec 1, 2020Phase 2 study in Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04661033 · 8 enrolled · United States, France, Germany and more
  11. May 31, 2022Phase 3 study in Plasma Cell Myeloma RecurrentNCT05405166 · 531 enrolled · United States, Argentina, Australia and more
  12. Dec 20, 2022Phase 2 study in Multiple MyelomaNCT05669989 · 70 planned · United States, Australia, Brazil and more
  13. Jan 20, 2023Phase 2 study in Multiple MyelomaNCT05704049 · 118 enrolled · Australia, Brazil, China and more
  14. Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571

Ahead

  1. Apr 5, 2027Primary completion: phase 3 study in Multiple MyelomaNCT03319667
  2. Nov 30, 2028Primary completion: phase 2 study in Multiple MyelomaNCT05669989
  3. Oct 14, 2030Primary completion: phase 3 study in Multiple MyelomaNCT04270409

TargetBeta

CD38 →read by rule
“A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 21 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05704049Multiple Myeloma · Australia, Brazil, China and more2Active, not recruitingDec 22, 2025118
NCT05669989Multiple Myeloma · United States, Australia, Brazil and more2By invitationNov 30, 202870
NCT05405166Plasma Cell Myeloma Recurrent · United States, Argentina, Australia and more3Active, not recruitingNov 6, 2024531
NCT04661033Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, France, Germany and more2TerminatedJun 26, 20238
NCT04294459Immune System Diseases · United States, Spain2TerminatedMay 2, 202223
NCT04270409Multiple Myeloma · United States, Australia, Brazil and more3Active, not recruitingOct 14, 2030337
NCT04045795Multiple Myeloma · United States, Australia, Belgium and more1CompletedMar 27, 202456
NCT03860844Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Argentina, Brazil and more2TerminatedSep 12, 202267
NCT03769181Lymphoma · France, Italy, Netherlands and more2TerminatedNov 8, 202258
NCT03733717Multiple Myeloma · China1CompletedSep 6, 202025
NCT03637764Neoplasms · United States, Belgium, Canada and more2TerminatedMay 11, 2022107
NCT03367819Prostatic Neoplasms · United States, France, Italy and more2TerminatedMar 10, 202144
NCT03319667Multiple Myeloma · United States, Australia, Belgium and more3Active, not recruitingApr 5, 2027475
NCT02999633Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · United States, Finland, France and more2TerminatedNov 14, 201714
NCT02990338Multiple Myeloma · United States, Australia, Belgium and more3CompletedNov 22, 2018307
NCT02812706Multiple Myeloma · Japan2CompletedJul 31, 201836
NCT02514668Multiple Myeloma · United States, Czechia, France1CompletedDec 2, 202155
NCT02513186Multiple Myeloma · France, Germany, Italy and more1CompletedJan 28, 202290
NCT02283775Multiple Myeloma · United States1CompletedMay 26, 202154
NCT01749969Multiple Myeloma · United States1CompletedJun 20, 202357
NCT01084252Hematologic Neoplasms · United States, Argentina, Belgium and more2CompletedDec 21, 2018351

How it is read

Names in the registry

  • “Isatuximab SAR650984”, 11 entries
  • “Isatuximab”, 6 entries
  • “isatuximab SAR650984”, 3 entries
  • “Isatuximab intravenous (IV)”, 1 entry
  • “Isatuximab subcutaneous (SC)”, 1 entry

Codes read as this program: SAR650984.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.